Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer E Amengual

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Blood|November 3, 2022
A Tet-a-Tet in T follicular helper cell lymphomaJennifer E Amengual
Hematology. American Society of Hematology. Education Program|December 4, 2020
Can we use epigenetics to prime chemoresistant lymphomas?Jennifer E Amengual
Blood|August 4, 2023
How I treat posttransplant lymphoproliferative disorderJennifer E Amengual, Barbara Pro
Leukemia & Lymphoma|June 25, 2010
Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphomaJennifer E Amengual, Bruce G Raphael
The Lancet. Haematology|June 30, 2022
Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphomaYun Kyoung Ryu, Jennifer E Amengual
Blood|April 27, 2023
Queen's gambit: response-adapted win in CAYA with cHLSeda S Tolu, Jennifer E Amengual
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2014
Manipulating the epigenome in germinal center lymphomas: is it getting easier and ezier?Jennifer E Amengual, Owen A O'Connor
Current Hematologic Malignancy Reports|August 17, 2018
Emerging EZH2 Inhibitors and Their Application in LymphomaJennifer K Lue, Jennifer E Amengual
Current Hematologic Malignancy Reports|February 5, 2018
The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL)Helen Ma, Ardy Davarifar, Jennifer E Amengual
Current Hematologic Malignancy Reports|September 7, 2019
Chromatin-Remodeled State in LymphomaYuxuan Liu, Yulissa Gonzalez, Jennifer E Amengual
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Blood|November 3, 2022
A Tet-a-Tet in T follicular helper cell lymphomaJennifer E Amengual
Hematology. American Society of Hematology. Education Program|December 4, 2020
Can we use epigenetics to prime chemoresistant lymphomas?Jennifer E Amengual
Blood|August 4, 2023
How I treat posttransplant lymphoproliferative disorderJennifer E Amengual, Barbara Pro
Leukemia & Lymphoma|June 25, 2010
Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphomaJennifer E Amengual, Bruce G Raphael
The Lancet. Haematology|June 30, 2022
Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphomaYun Kyoung Ryu, Jennifer E Amengual
Blood|April 27, 2023
Queen's gambit: response-adapted win in CAYA with cHLSeda S Tolu, Jennifer E Amengual
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2014
Manipulating the epigenome in germinal center lymphomas: is it getting easier and ezier?Jennifer E Amengual, Owen A O'Connor
Current Hematologic Malignancy Reports|August 17, 2018
Emerging EZH2 Inhibitors and Their Application in LymphomaJennifer K Lue, Jennifer E Amengual
Current Hematologic Malignancy Reports|February 5, 2018
The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL)Helen Ma, Ardy Davarifar, Jennifer E Amengual
Current Hematologic Malignancy Reports|September 7, 2019
Chromatin-Remodeled State in LymphomaYuxuan Liu, Yulissa Gonzalez, Jennifer E Amengual
Pageof 5